Table 1.
Effect of HM910 on inhibiting multiple myeloma cell NCI-H929 growth in vivo
| Group | Pre-experiment | Post-experiment | Tumor weight (g) | Inhibition ratio (%) | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| n | Weight (g) | n | Weight (g) | |||
| Control | 8 | 17.40 ± 0.70 | 8 | 20.60 ± 1.40 | 1.49 ± 0.89 | - |
| Topotecan 2 mg/kg | 8 | 17.20 ± 1.00 | 8 | 19.20 ± 1.30 | 0.71 ± 0.44* | 51.97 |
| HM910 35 mg/kg | 8 | 17.30 ± 0.70 | 8 | 18.80 ± 0.60 | 0.18 ± 0.36* | 88.18 |
| HM910 25 mg/kg | 8 | 17.30 ± 0.70 | 8 | 18.50 ± 0.70 | 0.27 ± 0.35* | 81.98 |
| HM910 18 mg/kg | 8 | 17.40 ± 0.80 | 8 | 19.20 ± 0.90 | 0.41 ± 0.34* | 72.67 |
| Control | 8 | 20.90 ± 1.10 | 8 | 21.50 ± 2.20 | 1.38 ± 0.91 | - |
| Topotecan 4 mg/kg | 8 | 20.70 ± 1.30 | 8 | 19.00 ± 2.20 | 0.31 ± 0.38* | 77.28 |
| HM910 35 mg/kg | 8 | 19.90 ± 0.80 | 8 | 17.30 ± 1.00 | 0.12 ± 0.08* | 90.93 |
| HM910 25 mg/kg | 8 | 20.60 ± 1.20 | 8 | 19.30 ± 1.20 | 0.26 ± 0.25* | 81.24 |
| HM910 18 mg/kg | 8 | 20.40 ± 0.90 | 8 | 19.30 ± 1.50 | 0.27 ± 0.20* | 80.64 |
*
P < 0.05 vs the control Group 1.
Means ± SD. n = 8.